Description: The NMTrypI concept is based on the development of innovative drug leads including a mechanism- based combination of a known and investigational drug and dual targets inhibition by using a common drug discovery platform. The platform is established by experts in their respective fields from SMEs and the public research sector in Europe and in disease-endemic countries.
NEW MEDICINES FOR TRYPANOSOMATIDIC INFECTIONS
Cover Story: In the New Medicines for Trypanosomatidic Infections (NMTRypI) project funded by the EU, we have discovered novel anti- leishmania and anti- trypanosoma hits that inhibit pteridine reductase 1 (PTR1). Here, we synthesized compounds with a flavanone scaffold and characterized their antiparasitic activity and ADME-tox properties. Crystal structure determination and computational docking explain differences in their inhibition of PTR1. Two crystal structures of one compound with different PTR1 enz
This project has received funding from European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 603240.